

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT

THE CENTER FOR DRUG EVALUATION, NMPA GRANTED PRIORITY REVIEW STATUS TO NDA FOR TD5CP ADOLESCENT AND ADULT

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Center for Drug Evaluation, National Medical Products Administration of the People's Republic of China (the “**NMPA**”) granted priority review status to the Company's new drug application (the “**NDA**”) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years old and above) (the “**Td5cp Adolescent and Adult**”). According to the requirement of national priority review and approval, the Center for Drug Evaluation, NMPA will prioritize resource allocation for the review of NDAs included in the scope of priority review and approval.

The Td5cp Adolescent and Adult is a booster vaccine for diphtheria, tetanus and acellular pertussis for adolescents and adults aged six years old and above. While major developed countries have already incorporated the vaccine into their routine vaccination programs, there is currently no approved booster vaccine for diphtheria, tetanus and acellular pertussis for adolescents and adults in China. Therefore, the successful launch of this product will address the existing gap in the domestic market. The Company's Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed for infants (below 2 years old) (the “**DT3cP Infant**”) obtained NDA approval in April 2026. As a diphtheria, tetanus and acellular pertussis (five-component) vaccine, the Td5cp Adolescent and Adult contains two additional pertussis antigen components compared to the DT3cP Infant. Each pertussis antigen can be purified separately and formulated in a defined ratio, thus ensuring batch-to-batch consistency of product quality and making the product more stable.

The Company is preparing to submit the NDA for its Td5cp Adolescent and Adult.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 11, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.